Patent No:
National Invention Patent for Patented Strain and Production Method of Vitamin K2 (MK-7)
A Bacillus Subtilis Natto and a Method for Producing MK-2
(Patent NO.ZL 2019 1 0593690.9)
Description:
Vitamin K2 contributes to bone and cardiovascular health. There are two vitamin K2 homologues, menaquinone-4 (MK-4) and menaquinone-7 (MK-7), that have been used as nutrients by the food industry and as nutritional supplements to support bone and cardiovascular health.
MK-4 is a shorter-chain of menaquinone, primarily found in animal products; whilst, MK-7 is a long-chain menaquinone found in natto, a traditional Japanese fermented soy food. MK-7 is generally considered more bioavailable and has a longer half-life in the body compared to MK-4.
Purity and Quality:
Natural Vitamin K2 produced by SungenBio is 100% all trans Vitamin K2 (MK-7) with the highest activity and a very high affinity for the human body. The internal control index is higher than ESP 39-NF34 standard. The ratio of trans vitamin K2 (MK-7) is ≥ 98%
Clinical Study:
Cardiovascular Health
Thrombosis and Haemostasis published research paper about “Enhance vascular reactivity and reduce vascular sclerosis in postmenopausal women” in 2015. The research indicated that carboxylation of bone matric protein influences the risk of calcification. Vitamin K2 keeps calcium out of the arteries and protect the blood vessels.
The Rotterdam Study “Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease” had followed more than 4800 initially healthy persons for over a 10-year period. The study shows that people who consumed most vitamin K2, had a 50% reduced risk of arterial calcification and also 50% risk reduction for cardiovascular, and 25% reduction of all cause mortality.
